goglides.dev
ResearchFinanceTechCompaniesDiscussion
Search
Sign inJoin
goglidesgoglides.devSocial learning for Finance and Tech.
TermsPrivacyDisclaimerModerationAcceptable UseDMCAContact
Company / Finance

Abeona Therapeutics Inc.

ABEO · NASDAQ

Official-source baseline for Abeona Therapeutics using SEC submissions, SEC company facts, the FY2025 10-K, latest available 10-Q, filed FY2025 results release, filed launch update, 2026 proxy materials, and FDA product approval sources.

FollowAdd to WatchlistAsk Question
NASDAQABEOCoverage BootstrapBiotechnologyGene TherapyRare Disease
OverviewFinancialsResearchTimelineCompareValuationScorecardDiscussion
Latest ReportMay 13, 2026Abeona Therapeutics (ABEO) Coverage Bootstrap: ZEVASKYN launch execution, manufacturing, payer access, and cash runwayView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 of 1 reports match
Clear filters
Selected tags
Rare Disease
Clear tags
Latest Thesis

Abeona Therapeutics (ABEO) Coverage Bootstrap: ZEVASKYN launch execution, manufacturing, payer access, and cash runway

Official-source baseline for Abeona Therapeutics using SEC submissions, SEC company facts, the FY2025 10-K, latest available 10-Q, filed FY2025 results release, filed launch update, 2026 proxy materials, and FDA product approval sources.

May 13, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Abeona Therapeutics Inc.Therapeutics (ABEO) Coverage Bootstrap: ZEVASKYN launch executioMay 13, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Abeona Therapeutics (ABEO) Coverage Bootstrap: ZEVASKYN launch execution, manufacturing, payer access, and cash runwayOfficial-source baseline for Abeona Therapeutics using SEC submissions, SEC company facts, the FY2025 10-K, latest available 10-Q, filed FY2025 results release, filed launch update, 2026 proxy materials, and FDA product approval sources.NASDAQMay 13, 2026Research reportReadSlides

Report Sources

No source records are attached to the current company reports.